Skip to main content
Top
Published in: Angiogenesis 3/2014

01-07-2014 | Original Paper

VEGFA gene locus analysis across 80 human tumour types reveals gene amplification in several neoplastic entities

Authors: Mariacarla Andreozzi, Luca Quagliata, Joel R. Gsponer, Christian Ruiz, Vincent Vuaroqueaux, Serenella Eppenberger-Castori, Luigi Tornillo, Luigi M. Terracciano

Published in: Angiogenesis | Issue 3/2014

Login to get access

Abstract

Background

Angiogenesis plays a pivotal role in neoplastic growth and metastasis formation. Vascular endothelial growth factor A (VEGFA) is a major player in physiological and tumour-induced angiogenesis and numerous human tumours have been show to overexpress VEGFA. Moreover increased VEGFA gene expression has been found frequently to correlate with tumour progression, recurrences and survival. Interestingly, several studies have demonstrated that gene amplification may result in protein overexpression and that amplification of the therapeutics’ target gene can serve as an excellent predictive marker (i.e. HER2 and trastuzumab). However the impact of VEGFA gene amplification has been only recently assessed for some cancer types such as osteosarcoma, colorectal, breast and liver cancer.

Aims

This study aimed to assess VEGFA gene amplification status using fluorescent in situ hybridization (FISH) in a large cohort of different tumour entities. Thus, we investigated the incidence of VEGFA amplification using a multi-tumour tissue microarray (TMA) containing 2,837 evaluable specimens from 80 different tumour entities and 31 normal tissue types. Moreover, we validated FISH analysis as reference method to evaluate VEGFA gene status by comparing it to comparative genomic hybridization (CGH).

Results

We observed that VEGFA locus amplification and/or polysomy represented a small but regularly detected population in several tumour entities while was not present in normal tissues. VEGFA gene alterations were predominantly observed in hepatocarcinomas, adenocarcinomas of the pancreas and intestine, large cell carcinoma of the lung and in endometrium serous carcinoma. Furthermore our data demonstrated that VEGFA detection by FISH provided highly comparable results to those generated by CGH.

Conclusion

Albeit with low percentage, VEGFA amplification is commonly observed across several tumour entities. Furthermore, our results demonstrated that FISH test could be used as a reliable diagnostic tool to evaluate VEGFA gene status in human specimens.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ellis LM, Hicklin DJ (2008) VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 8:579–591PubMedCrossRef Ellis LM, Hicklin DJ (2008) VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 8:579–591PubMedCrossRef
2.
go back to reference Eppenberger U, Kueng W, Schlaeppi JM, Roesel JL, Benz C, Mueller H et al (1998) Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients. JCO 16:3129–3136 Eppenberger U, Kueng W, Schlaeppi JM, Roesel JL, Benz C, Mueller H et al (1998) Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients. JCO 16:3129–3136
3.
go back to reference Hubbard J, Grothey A (2010) Antiangiogenesis agents in colorectal cancer. Curr Opin Oncol 22:374–380PubMedCrossRef Hubbard J, Grothey A (2010) Antiangiogenesis agents in colorectal cancer. Curr Opin Oncol 22:374–380PubMedCrossRef
4.
go back to reference Fan F, Samuel S, Gaur P, Lu J, Dallas NA, Xia L et al (2011) Chronic exposure of colorectal cancer cells to bevacizumab promotes compensatory pathways that mediate tumour cell migration. Br J Cancer 104:1270–1277PubMedCentralPubMedCrossRef Fan F, Samuel S, Gaur P, Lu J, Dallas NA, Xia L et al (2011) Chronic exposure of colorectal cancer cells to bevacizumab promotes compensatory pathways that mediate tumour cell migration. Br J Cancer 104:1270–1277PubMedCentralPubMedCrossRef
5.
6.
go back to reference Vlajnic T, Andreozzi MC, Schneider S, Tornillo L, Karamitopoulou E, Lugli A et al (2011) VEGFA gene locus (6p12) amplification identifies a small but highly aggressive subgroup of colorectal cancer [corrected] patients. Mod Pathol 24:1404–1412PubMedCrossRef Vlajnic T, Andreozzi MC, Schneider S, Tornillo L, Karamitopoulou E, Lugli A et al (2011) VEGFA gene locus (6p12) amplification identifies a small but highly aggressive subgroup of colorectal cancer [corrected] patients. Mod Pathol 24:1404–1412PubMedCrossRef
7.
go back to reference Schneider BP, Gray RJ, Radovich M, Shen F, Vance G, Li L et al (2013) Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial. Clin Cancer Res 19:1281–1289PubMedCentralPubMedCrossRef Schneider BP, Gray RJ, Radovich M, Shen F, Vance G, Li L et al (2013) Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial. Clin Cancer Res 19:1281–1289PubMedCentralPubMedCrossRef
8.
go back to reference Baumhoer D, Tornillo L, Stadlmann S, Roncalli M, Diamantis EK, Terracciano LM (2008) Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4,387 tissue samples. Am J Clin Pathol 129:899–906PubMedCrossRef Baumhoer D, Tornillo L, Stadlmann S, Roncalli M, Diamantis EK, Terracciano LM (2008) Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4,387 tissue samples. Am J Clin Pathol 129:899–906PubMedCrossRef
9.
go back to reference Heaphy CM, Subhawong AP, Hong SM, Goggins MG, Montgomery EA, Gabrielson E et al (2011) Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol 179:1608–1615PubMedCentralPubMedCrossRef Heaphy CM, Subhawong AP, Hong SM, Goggins MG, Montgomery EA, Gabrielson E et al (2011) Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol 179:1608–1615PubMedCentralPubMedCrossRef
10.
go back to reference Sauter G, Moch H, Carroll P, Kerschmann R, Mihatsch MJ, Waldman FM (1995) Chromosome-9 loss detected by fluorescence in situ hybridization in bladder cancer. IJC 64:99–103 Sauter G, Moch H, Carroll P, Kerschmann R, Mihatsch MJ, Waldman FM (1995) Chromosome-9 loss detected by fluorescence in situ hybridization in bladder cancer. IJC 64:99–103
11.
go back to reference Wolff AC, Hammond M, Schwartz JN et al (2007) American society of clinical oncology/college of american pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. JCO 25:118–145CrossRef Wolff AC, Hammond M, Schwartz JN et al (2007) American society of clinical oncology/college of american pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. JCO 25:118–145CrossRef
12.
go back to reference Salido M, Tusquets I, Corominas JM, Suarez M, Espinet B, Corzo C et al (2005) Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry. BCR 7:R267–R273PubMedCentralPubMedCrossRef Salido M, Tusquets I, Corominas JM, Suarez M, Espinet B, Corzo C et al (2005) Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry. BCR 7:R267–R273PubMedCentralPubMedCrossRef
13.
go back to reference Torrisi R, Rotmensz N, Bagnardi V, Viale G, Curto BD, Dell’orto P et al (2007) HER2 status in early breast cancer: relevance of cell staining patterns, gene amplification and polysomy 17. Eur J Cancer 43:2339–2344PubMedCrossRef Torrisi R, Rotmensz N, Bagnardi V, Viale G, Curto BD, Dell’orto P et al (2007) HER2 status in early breast cancer: relevance of cell staining patterns, gene amplification and polysomy 17. Eur J Cancer 43:2339–2344PubMedCrossRef
14.
go back to reference Tapia C, Savic S, Wagner U, Schonegg R, Novotny H, Grilli B et al (2007) HER2 gene status in primary breast cancers and matched distant metastases. BCR 9:R31PubMedCentralPubMedCrossRef Tapia C, Savic S, Wagner U, Schonegg R, Novotny H, Grilli B et al (2007) HER2 gene status in primary breast cancers and matched distant metastases. BCR 9:R31PubMedCentralPubMedCrossRef
15.
go back to reference Ma Y, Lespagnard L, Durbecq V, Paesmans M, Desmedt C, Gomez-Galdon M et al (2005) Polysomy 17 in HER-2/neu status elaboration in breast cancer: effect on daily practice. Clin Cancer Res 11:4393–4399PubMedCrossRef Ma Y, Lespagnard L, Durbecq V, Paesmans M, Desmedt C, Gomez-Galdon M et al (2005) Polysomy 17 in HER-2/neu status elaboration in breast cancer: effect on daily practice. Clin Cancer Res 11:4393–4399PubMedCrossRef
17.
go back to reference Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S et al (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5:R80PubMedCentralPubMedCrossRef Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S et al (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5:R80PubMedCentralPubMedCrossRef
18.
go back to reference Mike L, Smith JCM, Steven McKinney, Thomas Hardcastle and Natalie P (2009) Thorne snapCGH: Segmentation, normalisation and processing of aCGH data. R package version 1280 Mike L, Smith JCM, Steven McKinney, Thomas Hardcastle and Natalie P (2009) Thorne snapCGH: Segmentation, normalisation and processing of aCGH data. R package version 1280
19.
go back to reference Olshen AB, Venkatraman ES, Lucito R, Wigler M (2004) Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 5:557–572PubMedCrossRef Olshen AB, Venkatraman ES, Lucito R, Wigler M (2004) Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 5:557–572PubMedCrossRef
20.
go back to reference Olshen. VESaA. DNAcopy: DNA copy number data analysis. R package version 1320 Olshen. VESaA. DNAcopy: DNA copy number data analysis. R package version 1320
22.
go back to reference Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P, Minguez B et al (2008) Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res 68:6779–6788PubMedCentralPubMedCrossRef Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P, Minguez B et al (2008) Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res 68:6779–6788PubMedCentralPubMedCrossRef
23.
24.
go back to reference Knuutila S, Bjorkqvist AM, Autio K, Tarkkanen M, Wolf M, Monni O et al (1998) DNA copy number amplifications in human neoplasms: review of comparative genomic hybridization studies. Am J Pathol 152:1107–1123PubMedCentralPubMed Knuutila S, Bjorkqvist AM, Autio K, Tarkkanen M, Wolf M, Monni O et al (1998) DNA copy number amplifications in human neoplasms: review of comparative genomic hybridization studies. Am J Pathol 152:1107–1123PubMedCentralPubMed
25.
go back to reference Yoon HH, Shi Q, Sukov WR, Lewis MA, Sattler CA, Wiktor AE et al (2012) Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma. JCO 30:3932–3938CrossRef Yoon HH, Shi Q, Sukov WR, Lewis MA, Sattler CA, Wiktor AE et al (2012) Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma. JCO 30:3932–3938CrossRef
26.
go back to reference Tse CH, Hwang HC, Goldstein LC, Kandalaft PL, Wiley JC, Kussick SJ et al (2011) Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-HER2 targeted therapy. JCO 29:4168–4174CrossRef Tse CH, Hwang HC, Goldstein LC, Kandalaft PL, Wiley JC, Kussick SJ et al (2011) Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-HER2 targeted therapy. JCO 29:4168–4174CrossRef
27.
go back to reference Ley TJ et al (2013) Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 368:2059–2074CrossRef Ley TJ et al (2013) Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 368:2059–2074CrossRef
28.
go back to reference Barretina J, Taylor BS, Banerji S, Ramos AH, Lagos-Quintana M, Decarolis PL et al (2010) Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet 42:715–721PubMedCentralPubMedCrossRef Barretina J, Taylor BS, Banerji S, Ramos AH, Lagos-Quintana M, Decarolis PL et al (2010) Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet 42:715–721PubMedCentralPubMedCrossRef
29.
go back to reference Nagano A, Ohno T, Shimizu K, Hara A, Yamamoto T, Kawai G et al (2010) EWS/Fli-1 chimeric fusion gene upregulates vascular endothelial growth factor-A. IJC 126:2790–2798 Nagano A, Ohno T, Shimizu K, Hara A, Yamamoto T, Kawai G et al (2010) EWS/Fli-1 chimeric fusion gene upregulates vascular endothelial growth factor-A. IJC 126:2790–2798
30.
go back to reference Kreuter M, Paulussen M, Boeckeler J, Gerss J, Buerger H, Liebscher C et al (2006) Clinical significance of Vascular Endothelial Growth Factor-A expression in Ewing’s sarcoma. Eur J Cancer 42:1904–1911PubMedCrossRef Kreuter M, Paulussen M, Boeckeler J, Gerss J, Buerger H, Liebscher C et al (2006) Clinical significance of Vascular Endothelial Growth Factor-A expression in Ewing’s sarcoma. Eur J Cancer 42:1904–1911PubMedCrossRef
31.
go back to reference Yang J, Yang D, Sun Y, Sun B, Wang G, Trent JC et al (2011) Genetic amplification of the vascular endothelial growth factor (VEGF) pathway genes, including VEGFA, in human osteosarcoma. Cancer 117:4925–4938PubMedCentralPubMedCrossRef Yang J, Yang D, Sun Y, Sun B, Wang G, Trent JC et al (2011) Genetic amplification of the vascular endothelial growth factor (VEGF) pathway genes, including VEGFA, in human osteosarcoma. Cancer 117:4925–4938PubMedCentralPubMedCrossRef
32.
go back to reference Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D et al (2011) Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 91:1071–1121PubMedCentralPubMedCrossRef Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D et al (2011) Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 91:1071–1121PubMedCentralPubMedCrossRef
Metadata
Title
VEGFA gene locus analysis across 80 human tumour types reveals gene amplification in several neoplastic entities
Authors
Mariacarla Andreozzi
Luca Quagliata
Joel R. Gsponer
Christian Ruiz
Vincent Vuaroqueaux
Serenella Eppenberger-Castori
Luigi Tornillo
Luigi M. Terracciano
Publication date
01-07-2014
Publisher
Springer Netherlands
Published in
Angiogenesis / Issue 3/2014
Print ISSN: 0969-6970
Electronic ISSN: 1573-7209
DOI
https://doi.org/10.1007/s10456-013-9396-z

Other articles of this Issue 3/2014

Angiogenesis 3/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.